NVAX vs SRPT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NVAX · Novavax$10.78 ▲ 10.22%
SRPT · Sarepta Therapeutics$17.82 ▲ 1.42%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NVAX +51.6%
- SRPT +3.2%
Head to head
| Metric | NVAX | SRPT |
|---|---|---|
| Price | $10.78 | $17.82 |
| Change today | ▲ 10.22% | ▲ 1.42% |
| Market cap | $1.78B | $1.91B |
| Return, 3 months | +36.6% | +3.7% |
| Return, year to date | +60.4% | -17.2% |
| Return, 1 year | +44.9% | +1.1% |
| P/E (TTM) | – | – |
| P/B | -8.2 | 1.2 |
| P/E percentile vs own 5y | 11th | 47th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -76.3% | -34.3% |
| Net profit growth (YoY) | -150.1% | -102.5% |
| Gross margin | 78.6% | 59.1% |
| Operating margin | -32.9% | -3.2% |
| Net margin | -59.9% | -6.9% |
| Return on equity | – | -9.5% |
| Analyst target vs. price | -0.3% | +22.3% |
| Analyst buy share | 25% | 19% |
| RSI (14) | 52 | 46 |
| 30-day volatility | 109.4% | 54.0% |
| Max drawdown, 1 year | -34.6% | -39.2% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | Hold | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SRPT is the largest of the group by market value.
- NVAX has returned the most over the past year.
- SRPT is growing revenue fastest.
- SRPT keeps the most profit per dollar of sales.
- SRPT has been the calmest stock over the last 30 days.